<DOC>
	<DOC>NCT00276172</DOC>
	<brief_summary>The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.</brief_summary>
	<brief_title>Open-Label Natalizumab Safety Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Must give written informed consent. Must be an MS subject who has completed natalizumab Study C1801, C1802 or C1803 History of, or available abnormal laboratory results, indicative of any significant disease that would preclude treatment. History of severe allergic or anaphylactic reactions or known drug hypersensitivity A clinically significant infectious illness within 30 days prior to study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>